Janus Henderson Group PLC Has $52.65 Million Stake in Inogen Inc (INGN)

Janus Henderson Group PLC lifted its position in Inogen Inc (NASDAQ:INGN) by 15,943.5% during the 1st quarter, HoldingsChannel reports. The fund owned 552,056 shares of the medical technology company’s stock after buying an additional 548,615 shares during the quarter. Janus Henderson Group PLC’s holdings in Inogen were worth $52,650,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the company. BlackRock Inc. increased its position in shares of Inogen by 4.4% in the fourth quarter. BlackRock Inc. now owns 2,233,303 shares of the medical technology company’s stock worth $277,307,000 after acquiring an additional 93,873 shares in the last quarter. Norges Bank purchased a new position in shares of Inogen in the fourth quarter worth approximately $48,104,000. Northern Trust Corp increased its position in shares of Inogen by 18.6% in the fourth quarter. Northern Trust Corp now owns 293,842 shares of the medical technology company’s stock worth $36,487,000 after acquiring an additional 46,036 shares in the last quarter. Jennison Associates LLC increased its position in shares of Inogen by 90.2% in the fourth quarter. Jennison Associates LLC now owns 232,179 shares of the medical technology company’s stock worth $28,830,000 after acquiring an additional 110,098 shares in the last quarter. Finally, Chicago Capital LLC increased its position in shares of Inogen by 66.1% in the first quarter. Chicago Capital LLC now owns 222,235 shares of the medical technology company’s stock worth $21,195,000 after acquiring an additional 88,449 shares in the last quarter. 98.63% of the stock is currently owned by institutional investors and hedge funds.

INGN stock opened at $72.24 on Friday. The company has a market cap of $2.01 billion, a P/E ratio of 31.41, a P/E/G ratio of 3.06 and a beta of 1.39. Inogen Inc has a 52 week low of $64.01 and a 52 week high of $287.79.

Inogen (NASDAQ:INGN) last posted its quarterly earnings results on Tuesday, May 7th. The medical technology company reported $0.24 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.05). The company had revenue of $90.20 million for the quarter, compared to analyst estimates of $89.69 million. Inogen had a return on equity of 18.60% and a net margin of 14.48%. The business’s revenue for the quarter was up 14.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.48 earnings per share. Analysts anticipate that Inogen Inc will post 1.91 EPS for the current year.

Several research analysts have recently weighed in on the stock. BidaskClub downgraded shares of Inogen from a “sell” rating to a “strong sell” rating in a research report on Saturday, April 13th. Needham & Company LLC dropped their target price on shares of Inogen from $191.00 to $111.00 and set a “strong-buy” rating on the stock in a research report on Wednesday. JPMorgan Chase & Co. dropped their target price on shares of Inogen to $175.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 27th. Stifel Nicolaus dropped their target price on shares of Inogen from $160.00 to $85.00 and set a “buy” rating on the stock in a research report on Wednesday. Finally, Piper Jaffray Companies dropped their target price on shares of Inogen from $290.00 to $185.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 27th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $121.60.

TRADEMARK VIOLATION NOTICE: This article was first published by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://www.baseballdailydigest.com/news/2019/05/10/janus-henderson-group-plc-has-52-65-million-stake-in-inogen-inc-ingn.html.

Inogen Profile

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Featured Article: Federal Reserve

Want to see what other hedge funds are holding INGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inogen Inc (NASDAQ:INGN).

Institutional Ownership by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.